{"nctId":"NCT01801436","briefTitle":"A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma","startDateStruct":{"date":"2006-12"},"conditions":["Multiple Myeloma"],"count":14,"armGroups":[{"label":"Bortezomib","type":"EXPERIMENTAL","interventionNames":["Drug: Bortezomib"]}],"interventions":[{"name":"Bortezomib","otherNames":["VELCADE"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants previously diagnosed with multiple myeloma based on standard criteria\n* Participant has received at least 2 previous lines of therapy for multiple myeloma and, in the Investigator's opinion, currently requires therapy because of relapsed (the return of a medical problem) or progressive disease\n* Female participants either postmenopausal or surgically sterilized or willing to use an acceptable method of birth control from Screening through the Final Visit\n* If male, the participant agrees to use an acceptable barrier method for contraception from Screening through the Final Visit\n* Participant has a Karnofsky performance status classifies participants as to their functional impairment and is used to compare effectiveness of different therapies and to assess the prognosis \\[outlook, probable outcomes\\] in individual participants) greater than 60\n\nExclusion Criteria:\n\n* If the participant received bortezomib in a previous trial, the Participants' best response to bortezomib must be progressive disease\n* If the participant received bortezomib in a previous trial, the participant must have experienced 1 or more serious adverse events\n* Participants who have received nitrosoureas within 6 weeks or any other chemotherapy (treatment of disease, usually cancer, by chemical agents) within 3 weeks before enrollment\n* Participants who have received corticosteroids (greater than 10 milligram per day prednisone or equivalent) within 3 weeks before enrollment\n* Human Immunodeficiency Virus (HIV - a life-threatening infection which you can get from an infected person's blood or from having sex with an infected person)-positive or hepatitis-B surface antigen-positive participants or participants with known active hepatitis-C infection","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Response to Treatment at Day 1 of Cycle 5","description":"Response to treatment was based on the changes in monoclonal protein (M-protein) in serum and urine. Response categories were complete response: complete clearance of M-protein for at least 6 weeks, response: at least 75 percent reduction in M-protein for at least 2 determinations 6 weeks apart, partial response: 50 to 74 percent reduction in M-protein, minimal response: 25 to 49 percent reduction in M-protein, stable disease: not qualifying minimal response or progression and progression: increased M-protein level in serum or urine or clinical signs of disease progression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Response to Treatment at Day 1 of Cycle 7","description":"Response to treatment was based on the changes in monoclonal protein (M-protein) in serum and urine. Response categories were complete response: complete clearance of M-protein for at least 6 weeks, response: at least 75 percent reduction in M-protein for at least 2 determinations 6 weeks apart, partial response: 50 to 74 percent reduction in M-protein, minimal response: 25 to 49 percent reduction in M-protein, stable disease: not qualifying minimal response or progression and progression: increased M-protein level in serum or urine or clinical signs of disease progression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Response to Treatment at Day 11 of Cycle 8","description":"Response to treatment was based on the changes in monoclonal protein (M-protein) in serum and urine. Response categories were complete response: complete clearance of M-protein for at least 6 weeks, response: at least 75 percent reduction in M-protein for at least 2 determinations 6 weeks apart, partial response: 50 to 74 percent reduction in M-protein, minimal response: 25 to 49 percent reduction in M-protein, stable disease: not qualifying minimal response or progression and progression: increased M-protein level in serum or urine or clinical signs of disease progression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Karnofsky Performance Status (KPS) Score at Baseline","description":"The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With KPS Score at Day 1 of Cycle 1","description":"The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With KPS Score at Day 1 of Cycle 3","description":"The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With KPS Score at Day 1 of Cycle 5","description":"The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With KPS Score at Day 1 of Cycle 7","description":"The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With KPS Score at Day 11 of Cycle 8","description":"The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Maximum Observed Plasma Concentration (Cmax) of Bortezomib on Day 1 of Cycle 1","description":"The Cmax is observed maximum plasma concentration, taken directly from the plasma concentration-time profile.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.43","spread":"38.47"}]}]}]},{"type":"PRIMARY","title":"Maximum Observed Plasma Concentration (Cmax) of Bortezomib on Day 11 of Cycle 1","description":"The Cmax is observed maximum plasma concentration, taken directly from the plasma concentration-time profile.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"127.02","spread":"59.80"}]}]}]},{"type":"PRIMARY","title":"Time to Reach Maximum Observed Plasma Concentration (Tmax) of Bortezomib on Day 1 of Cycle 1","description":"Tmax is the time when Cmax is observed, taken directly from the plasma concentration-time profile.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.00"}]}]}]},{"type":"PRIMARY","title":"Time to Reach Maximum Observed Plasma Concentration (Tmax) of Bortezomib on Day 11 of Cycle 1","description":"Tmax is the time when Cmax is observed, taken directly from the plasma concentration-time profile.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.01"}]}]}]},{"type":"PRIMARY","title":"Elimination Half-Life Period (T1/2) of Bortezomib on Day 1 of Cycle 1","description":"The T1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal rate-constant (lambda\\[z\\]) of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.07"}]}]}]},{"type":"PRIMARY","title":"Elimination Half-Life Period (T1/2) of Bortezomib on Day 11 of Cycle 1","description":"The T1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal rate-constant (lambda\\[z\\]) of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.55","spread":"87.20"}]}]}]},{"type":"PRIMARY","title":"Terminal Rate Constant (Lambda[z]) of Bortezomib on Day 1 of Cycle 1","description":"Lambda(z) is defined as terminal rate-constant which reflect the speed of drug elimination in vivo (within the living), and is estimated by log-linear regression analysis of the terminal phase of the plasma concentration versus time curve for at least 3 points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.07"}]}]}]},{"type":"PRIMARY","title":"Terminal Rate Constant (Lambda[z]) of Bortezomib on Day 11 of Cycle 1","description":"Lambda(z) is defined as terminal rate-constant which reflect the speed of drug elimination in vivo (within the living), and is estimated by log-linear regression analysis of the terminal phase of the plasma concentration versus time curve for at least 3 points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.01"}]}]}]},{"type":"PRIMARY","title":"Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[0-t]) of Bortezomib on Day 1 of Cycle 1","description":"The AUC(0-t) is area under the plasma concentration-time curve from time zero to the last quantifiable concentration determined by the trapezoidal rule.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.86","spread":"30.56"}]}]}]},{"type":"PRIMARY","title":"Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[0-t]) of Bortezomib on Day 11 of Cycle 1","description":"The AUC(0-t) is area under the plasma concentration-time curve from zero to the last quantifiable concentration determined by the trapezoidal rule.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"190.39","spread":"55.27"}]}]}]},{"type":"PRIMARY","title":"Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Bortezomib on Day 1 of Cycle 1","description":"The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z), in which C(last) is the last observed quantifiable concentration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106.99","spread":"126.91"}]}]}]},{"type":"PRIMARY","title":"Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Bortezomib on Day 11 of Cycle 1","description":"The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z), in which C(last) is the last observed quantifiable concentration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"349.62","spread":"178.81"}]}]}]},{"type":"PRIMARY","title":"Area Under First Moment Plasma Concentration-Time Curve (AUMC) of Bortezomib on Day 1 of Cycle 1","description":"AUMC is defined as the area under first moment plasma concentration-time curve from time of dosing up to definite time t, to infinity, or to the time of last measurable concentration determined by the following equation: AUMC(0 to infinity)=Cntn/k elimination(el) + Cn/k(el\\^2) summation\\[(tn - tn\\^-1) (Cn\\^-1) (tn\\^-1)\\] + Cntn/2 where Cn=last quantifiable concentration, tn=time at which Cn is measured, k=rate constant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20678.41","spread":"54596.1"}]}]}]},{"type":"PRIMARY","title":"Area Under First Moment Plasma Concentration-Time Curve (AUMC) of Bortezomib on Day 11 of Cycle 1","description":"AUMC is defined as the area under first moment plasma concentration-time curve from time of dosing up to definite time t, to infinity, or to the time of last measurable concentration determined by the following equation: AUMC(0 to infinity)=Cntn/k elimination(el) + Cn/k(el\\^2) summation\\[(tn - tn\\^-1) (Cn\\^-1) (tn\\^-1)\\] + Cntn/2 where Cn=last quantifiable concentration, tn=time at which Cn is measured, k=rate constant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39414.06","spread":"51021.07"}]}]}]},{"type":"PRIMARY","title":"Mean Residence Time (MRT) of Bortezomib in the Body on Day 1 of Cycle 1","description":"The MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(infinity)/AUC(infinity) where AUMC(infinity) is area under the plasma concentration-time first moment curve from time zero to infinite time and AUC(infinity) is the area under the plasma concentration-time curve from time zero to infinite time.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.97","spread":"121.65"}]}]}]},{"type":"PRIMARY","title":"Mean Residence Time (MRT) of Bortezomib in the Body on Day 11 of Cycle 1","description":"The MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(infinity)/AUC(infinity) where AUMC(infinity) is area under the plasma concentration-time first moment curve from time zero to infinite time and AUC(infinity) is the area under the plasma concentration-time curve from time zero to infinite time.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.74","spread":"58.38"}]}]}]},{"type":"PRIMARY","title":"Systemic Clearance (CL) of Bortezomib on Day 1 of Cycle 1","description":"Systemic CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-infinity).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.99","spread":"18.54"}]}]}]},{"type":"PRIMARY","title":"Systemic Clearance (CL) of Bortezomib on Day 11 of Cycle 1","description":"Systemic CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-infinity).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.68","spread":"2.46"}]}]}]},{"type":"PRIMARY","title":"Volume of Distribution at Steady-State (Vss) of Bortezomib on Day 1 of Cycle 1","description":"Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state which is estimated by (D/AUC\\[0-infinity\\])\\*(AUMC\\[0-infinity\\])/AUC\\[0-infinity\\]) where D is the dose of study drug, AUMC(0-infinity) is the area under the first moment curve extrapolated to infinity and AUC(0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"483.71","spread":"403.04"}]}]}]},{"type":"PRIMARY","title":"Volume of Distribution at Steady-State (Vss) of Bortezomib on Day 11 of Cycle 1","description":"Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state which is estimated by (D/AUC\\[0-infinity\\])\\*(AUMC\\[0-infinity\\])/AUC\\[0-infinity\\]) where D is the dose of study drug, AUMC(0-infinity) is the area under the first moment curve extrapolated to infinity and AUC(0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"331.68","spread":"85.81"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":14},"commonTop":["Neutrophil count decreased","White blood cell count decreased","Platelet count decreased","Haemoglobin decreased","Diarrhoea"]}}}